FGFR

Fibroblast growth factors (FGFs) comprise a large family of signaling polypeptides. In the adult organism, FGFs are homeostatic factors and function in tissue repair and response to injury. In the embryo, FGFs regulate cell proliferation, migration, differentiation and survival. When inappropriately expressed, some FGFs can contribute to developmental defects and to the pathogenesis of cancer and other diseases. Mutations in FGF receptor tyrosine kinases (FGFRs) in humans causes skeletal diseases such as Achondroplasia, the most common form of dwarfism in humans, and Craniosynostosis syndromes, a cluster of diseases that involves premature fusion of cranial bones. In vertebrates, 22 Fgf genes encode polypeptides that range in molecular mass from 17 to 34 kDa. Eighteen of the 22 FGFs bind and activate a subset of seven distinct high affinity FGFRs that are derived by alternative splicing of four genes. Affinity and specificity of FGFs for their receptors is regulated by alternative mRNA splicing in three of the four known Fgfr tyrosine kinase genes. FGF activity and specificity is further regulated by heparin sulfate proteoglycans, which serve as co-receptors for FGFs.

FGF receptors (FGFR) contain three extracellular immunoglobulin-like (Ig) domains and a heparin binding sequence. Alternative mRNA splicing in the carboxy-terminal half of Ig-domain III creates b and c isoforms of Fgfrs 1-3. Fgfr alternative splicing is regulated in a tissue-specific manner and dramatically affects ligand-receptor binding specificity. The b splice form is utilized in epithelial lineages and the c splice is utilized in mesenchymal lineages. Ligands specific for these receptor splice forms are expressed in adjacent tissues resulting in directional epithelial-mesenchymal signaling. For example, FGFR2b is expressed in many epithelial tissues and can be activated by FGF7, FGF10 and FGF22, ligands produced in mesenchymal tissue. These ligands show no activity towards mesenchymally expressed FGFR2c. Conversely, ligands such as FGFs 4, 8 and 9 are expressed in epithelial-like tissue and activate c splice forms of Fgfrs.

An important feature of FGF biology involves the interaction between FGF and heparin and heparan sulfate proteoglycans (HSPG). Heparin and heparan sulfate stabilizes FGFs to thermal denaturation and proteolysis, limits the diffusion and release of FGFs into interstitial spaces, and regulates the binding affinity and specificity of FGFs for their receptors. Heparin or heparan sulfate is required for FGF to effectively activate an FGFR in cells that are deficient in or unable to synthesize HSPG or in cells pretreated with heparin degrading enzymes or inhibitors of sulfation. Mutations in enzymes involved in heparan biosynthesis also affect FGF signaling pathways during development.

FGFRs are receptor tyrosine kinases that are activated by ligand-induced dimerization and subsequent auto-phosphorylation. FGFs bind to FGFRs in a 1:1 complex that is facilitated by heparin/heparan sulfate, which makes numerous contacts with both the FGF and FGFR molecule. Heparin/heparan sulfate also interacts with an adjoining FGFR to promote FGFR dimerization. The activated FGFR interacts with intracellular signaling molecules allowing it to couple to several signal transduction pathways. The two primary pathways activated by the FGF receptor are the ras-raf-map kinase pathway and the phospholipase C-gamma (PLC-γ) pathway. An adapter protein, FRS2, couples the FGFR to MAP kinase and phosphatidylinositol-3 (PI-3) kinase activation, chemotactic response, and cell proliferation. The mitogenic response to FGF is likely to require activation of map kinase and possibly p38; however, the ability of FGFs to regulate differentiation and embryonic patterning may involve the ras, PLC-γ or novel pathways. For example, the anti-proliferative effects of FGF on chondrocytes are likely to be mediated through STAT1. Feedback inhibition of FRS2 is regulated by MAP kinase phosphorylation of multiple threonine residues in response to FGF, insulin, EGF, and PDGF extracellular signals. Differential signaling in diverse cell types is also a consequence of sequence differences between the four FGF receptors and possible alternative splicing within the cytoplasmic domain.

Two main classes of small molecule inhibitors have been identified. The SU compounds contain a substituted oxindole core (indolinone) while the PD compounds have a substituted pyrido[2,3-d]pyrimidine core. Crystallographic studies show that both SU5402 and PD173074 bind in the ATP-binding cleft of the FGFR1 tyrosine kinase domain between the two lobes of the kinase. It is likely that these molecules inhibit all FGFRs.

 

The Table below contains accepted modulators and additional information. For a list of additional products, see the "Similar Products" section below.

 

Family Members FGFR1 FGFR2 FGFR3 FGFR4 FGFR5
Other Names Fms-like tyrosine kinase 2
c-fgr
FLG
FLT2
Cek-1
BEK
KSAM
Cek-3
KGFR
JTK4
Cek-2
flg-2
JTK2
TKF
Not Known
Molecular Weight 91.8 kDa 92 kDa
87.7 kDa
87.9 kDa
54.5 kDa
Structural Data 822 aa 821 aa 806 aa 802 aa 504 aa
Isoforms 18 19 3 Not Known Not Known
Species Human
Mouse
Rat
Chicken
Xenopus
Human
Mouse
Xenopus
Human
Mouse
Human
Mouse
Human
Domain
Organization
3 Ig-like C2-type domains
Protein kinase domain
3 Ig-like C2-type domains
Protein kinase domain
3 Ig-like C2-type domains
Protein kinase domain
3 Ig-like C2-type domains
Protein kinase domain
2 Ig-like C2-type domains
Phosphorylation
Sites
Tyr463
Tyr583
Tyr585
Tyr653
Tyr654
Tyr730
Tyr766
Tyr657 Tyr648 Tyr643 Not Known
Tissue
Distribution
Placenta
Brain
Liver
Lungs
Uterus
Brain
Kidney
Skin
Lung
Liver
Brain
Kidney
Testis
Myoblasts
Lung
Liver
Kidney
Mesenchymal
Kidney
Brain
Lung
Subcellular
Localization
Plasma membrane Plasma membrane Plasma membrane Plasma membrane Plasma membrane
Binding Partners/
Associated Proteins
FGF2 FGF1 and FGF2 FGF1 FGF19 Not known  
Upstream
Activators
FGF-1,2,4 FGF-1,2,4,7 FGF-1,2,4,9 FGF-1,2 FGF-1,2
Downstream
Activation
Sprouty 2
Shp2
PLC-γ
STAT1
STAT3
MAPK
PI3K
Sprouty 2
Shp2
PLC-γ
STAT1
STAT3
MAPK
PI3K
Shp2
PLC-γ
STAT1
STAT3
MAPK
PI3K
Shp2
PLC-γ
STAT1
STAT3
MAPK
PI3K
Not Known
Activators Not Known Not Known Not Known Not Known  
Inhibitors SU5402 (SML0443)
PD166285 (PZ0116)
PD173074 (P2499)
PD161570 (PZ0109)
PD166866 (PZ0114)
SU5402 (SML0443)
PD166285 (PZ0116)
PD173074 (P2499)
PD161570 (PZ0109)
PD166866 (PZ0114)
SU5402 (SML0443)
PD166285 (PZ0116)
PD173074 (P2499)
PD161570 (PZ0109)
PD166866 (PZ0114)
SU5402 (SML0443)
PD166285 (PZ0116)
PD173074 (P2499)
PD161570 (PZ0109)
PD166866 (PZ0114)
Not Known
Selective
Activators
Not Known Not Known Not Known Not Known Not Known
Phyiological
Function
Cell activation
Chemotactic response
Cell proliferation
Cell differentiation
Embryonic patterning
Cell activation
Chemotactic response
Cell proliferation
Cell differentiation
Embryonic patterning
Cell activation
Chemotactic response
Cell proliferation
Cell differentiation
Embryonic patterning
Cell activation
Chemotactic response
Cell proliferation
Cell differentiation
Embryonic patterning
Not Known
Disease
Relevance
Pfeiffer syndrome
Kallmann syndrome
Stem cell leukemia
Lymphoma
Crouzon syndrome
Jackson-Weiss syndrome
Apert syndrome
Pfeiffer syndrome
Beare-Stevenson cutis gyrata syndrome
Achondroplasia
Crouzon syndrome
Thanatophoric dysplasia
Bladder cancer
Cervical cancer
Craniosynostosis Adelaide type
Multiple myeloma
Thyroid cancer Not Known

 

Abbreviations

PD161570: 1-Tert-butyl-3-[6-(2,6-dichloro-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]urea
PD166285: 6-(2, 6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-Pyrido[2, 3-d]pyrimidin-7(8H)-one dihydrochloride
PD166866: 1-[2-Amino-6-(3,5-dimethyoxy-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea
PD173074: N-[2-[[4-(diethylamino)butyl]amino-6-(3, 5-dimethoxyphenyl)pyrido[2, 3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea
SU5402: 3-[4-Methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid

 

Similar Products


     

References